N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
“With DEFINITY ® already widely used in the intensive care unit settings, the results confirm that there is a survival advantage associated with using echocardiogram contrast agents appropriately,” ...
“The label change implemented by FDA is reflective of both the extensive data on contrast agents and the well characterized and stable safety profile of DEFINITY, which has been used to perform more ...
October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Please provide your email address to receive an email when new articles are posted on . Lantheus Medical Imaging Inc. announced that the FDA has approved a label update that removes the ...
NORTH BILLERICA, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results